The Prevalence of Multiple Sclerosis in 3 US Communities by Williamson, Dhelia M. et al.
VOLUME 7: NO. 1 JANUARY 2010
The Prevalence of Multiple Sclerosis  
in 3 US Communities
 ORIGINAL RESEARCH
Suggested citation for this article: Noonan CW, Williamson 
DM, Henry JP, Indian R, Lynch SG, Neuberger JS, et al. 
The  prevalence  of  multiple  sclerosis  in  3  US  communi-
ties. Prev Chronic Dis 2010;7(1). http://www.cdc.gov/pcd/
issues/2010/jan/08_0241.htm. Accessed [date].
PEER REVIEWED
Abstract
 
Introduction
We estimated the prevalence of multiple sclerosis (MS) 
in 3 large geographic areas in the southern, middle, and 
northern United States.
 
Methods
The  primary  data  source  was  medical  records  from 
office visits to private neurologists’ practices or to neurol-
ogy departments in tertiary care facilities during a 3-year 
period. Additional data sources included patient advocacy 
groups, nursing homes, and general practitioners.
 
Results
Three-year  US  age-adjusted  prevalence  estimates  for 
the  study  areas  varied  substantially.  The  prevalence 
was  lowest  (47.2  per  100,000  population)  in  the  Texas 
study area (33°30′ north latitude), intermediate (86.3 per 
100,000  population)  in  the  Missouri  study  area  (39°07′ 
north latitude), and highest (109.5 per 100,000 population) 
in the Ohio study area (41°24′ north latitude). The geo-
graphic differences remained strong after age-adjustment 
to the world standard population. The inverse association 
between UV light exposure and MS prevalence estimates 
was consistent with this observed latitude gradient. In all 
3 areas, MS prevalence was highest among women, people 
aged 40 to 59 years, and non-Hispanics.
 
Conclusion
These  results  provide  necessary  prevalence  estimates 
for community cluster investigations and establish base-
line  estimates  for  future  studies  to  evaluate  temporal 
trends in disease prevalence.
Introduction
 
Multiple sclerosis (MS) is an inflammatory demyelinat-
ing disease of unknown origin; it affects more than 1 mil-
lion  people  worldwide  (1)  and  disproportionately  affects 
women  and  whites  (2).  Approximately  85%  of  affected 
people  have  a  relapsing-remitting  course,  characterized 
by an unpredictable course of exacerbations and remis-
sions (3). Ultimately, most patients become disabled and 
may or may not have superimposed relapses (secondary 
progressive MS) (3,4). Approximately 15% of patients have 
primary progressive MS, in which the condition worsens 
gradually from disease onset and is not associated with 
relapses (5).
 
The ability of a public health agency to enumerate cases 
and determine whether an excess of cases is present in a 
particular community is compromised by the lack of MS 
registries, the range of disease severity, which can affect 
ascertainment, and unknown background prevalence esti-
mates. Prevalence estimates for MS vary from 58 to 95 per 
100,000 population in the United States (6-8). In the past 
25 years, prevalence studies of specific US locales have 
produced a range of estimates (9), up to 177 per 100,000 
population in Olmstead County, Minnesota (10). Our goal 
was  to  determine  MS  prevalence  estimates  for  3  areas 
in the southern, middle, and northern United States to 
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be used as regional comparisons for community-specific 
investigations of MS prevalence and as baseline estimates 
for studies of temporal trends in prevalence.
Methods
Study areas
 
The  areas  we  studied  were  Lorain  County,  Ohio;  the 
cities of Sugar Creek and Independence, Missouri; and 19 
counties surrounding Lubbock, Texas. Lorain County (pop-
ulation 284,664) was included in this study because the 
community had expressed concerns about the frequency 
of MS in the city of Wellington (population 3,171) and the 
possible health risks of proximity to an iron foundry and 
plastics company. Results from a previous cluster investi-
gation in Wellington identified 27 cases of MS for a crude 
point prevalence estimate of 651 per 100,000 persons, but 
this assessment was limited by the lack of appropriate US 
comparison prevalence estimates for Ohio (11).
 
Another  community,  Sugar  Creek,  expressed  similar 
concerns about a perceived excess of MS cases and was 
near an oil refinery that operated in the area from 1904 
to 1982 (12). Although refinery operations ceased in 1982, 
portions of the site are still used as a light-oil petroleum 
product  marketing  terminal,  a  pipeline  facility,  and  an 
asphalt receiving and processing center. Because of the 
small size of Sugar Creek (population 9,915), the adjacent 
city of Independence (population 110,884) was included for 
comparison.
 
The 19-county area around Lubbock (population 424,916) 
was  proposed  to  provide  MS  prevalence  estimates  for 
comparison  with  a  previous  MS  cluster  investigation 
conducted in El Paso, Texas (13). In all 3 previous cluster 
investigations, the lack of an appropriate comparison for 
MS prevalence estimates precluded an assessment of the 
true effect of the disease.
Case ascertainment
 
The  primary  data  source  for  case  ascertainment  was 
medical records from the offices of neurologists practicing 
in the study area or in contiguous areas or from the neurol-
ogy departments of local hospitals. In Ohio, this included 
offices  and  hospitals  in  Lorain  and  Cuyahoga  counties, 
including the Cleveland Clinic, 8 private neurologists, and 
5 hospitals. In Missouri, this included offices and hospitals 
in Clay and Jackson counties, Missouri, and Johnson and 
Wyandotte  counties,  Kansas,  including  12  private  neu-
rologists and 8 hospitals that provided neurologic care. In 
Texas, the Texas Tech University Medical System and 8 
private neurologists provided neurologic specialty services 
and care for the study area.
 
Residence was determined by the address in the patient’s 
medical record. Records were included if patients had an 
office visit from January 1, 1998, through December 31, 
2000, and had the following International Classification of 
Disease, 9th Revision, codes or corresponding conditions: 
MS  (340),  other  demyelinating  diseases  (341.8-341.9), 
transverse myelitis (323.9), and optic neuritis (377.3).
 
We used additional data sources to evaluate the com-
pleteness of case ascertainment, including patient advo-
cacy  groups  (the  National  Multiple  Sclerosis  Society), 
nursing homes, general practitioners, and death certifi-
cates. Self-reports were not actively sought; however, if 
people with potential cases identified themselves to study 
personnel, they were asked to provide the name of their 
treating  physician.  Similarly,  treating  physicians  were 
identified for any potential cases identified through MS 
advocacy groups or nursing homes. If not already included 
in the surveillance effort, all medical records that met the 
inclusion criteria were abstracted from the treating phy-
sician’s office. This study was approved by institutional 
review boards in each study area and by the Centers for 
Disease Control and Prevention.
Case verification
 
Trained abstractors, who were supervised by the project 
investigators and neurologists, used a standard form that 
included history of relapses, neurologic examination find-
ings, and results of evoked potentials, cerebrospinal fluid 
examination, and magnetic resonance imaging of the brain 
and  cervical  spine.  Abstractors  also  recorded  sex,  race/
ethnicity, occupation, family history of MS, country/state 
of birth, treating physician’s MS diagnosis, criteria used 
to determine diagnosis, and dates of symptom onset and 
diagnosis. Individual identifiers (name, address, and Social 
Security number) were recorded to ensure accurate case 
counts and to avoid duplicate counting from other sources.
 
The  abstracted  records  of  all  patients  with  potential 
MS  cases  were  evaluated  by  reviewing  neurologists  in VOLUME 7: NO. 1
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each study area according to the Poser criteria (14). We 
chose the Poser criteria because they were the criteria in 
use during the period evaluated. Each case was classified 
as definite (clinical or laboratory supported) or probable 
(clinical or laboratory supported) MS. We also considered 
2 additional disease classification categories. The category 
of  presumptive  MS  was  used  for  cases  for  which  data 
were insufficient to satisfy clinical criteria but for which a 
diagnosis seemed correct after review, and the category of 
unknown was used when data were insufficient to deter-
mine the presence or absence of MS. If necessary to clas-
sify a specific case, the neurologist directed the abstractor 
to  collect  additional  information.  We  used  only  definite 
and  probable  categories  to  calculate  prevalence  for  this 
analysis.
Exposure to UV radiation
 
To explore the geographic difference in MS prevalence 
estimates, we evaluated the differences in UV radiation 
exposure between study regions. Patterns of exposure to 
UV radiation are similar to patterns of distribution of MS 
in some areas, which suggests a possible contribution to 
MS risk (15,16). We used archived data from the National 
Weather Service’s UV Index Forecast averaged for 1997 
through 2001 for sites near our study areas (17). The UV 
Index Forecast is the scaled erythemal (skin reddening) 
dose  rate  integrated  over  the  UVB  and  UVA  spectral 
bands.  The  data  were  summarized  according  to  World 
Health  Organization  categories  from  low  to  extreme. 
The UV data locations (and their approximate distance 
from  the  respective  study  areas)  were  Cleveland,  Ohio 
(29 miles); Saint Louis, Missouri (249 miles); and Dallas, 
Texas (347 miles). Each of these surrogate locations was in 
the same state and at approximately the same latitude as 
its respective study area.
Data analysis
 
We  calculated  age-  and  sex-specific  period  prevalence 
estimates  by  using  the  definite  and  probable  MS  cases 
ascertained from 1998 through 2000 as the numerator and 
the 2000 census counts for the study areas as the denomi-
nator.  Overall  prevalence  estimates  for  each  area  were 
directly race-adjusted to the US 2000 race/ethnicity dis-
tribution and age-adjusted to the US 2000 and the world 
standard  populations  (18,19).  The  differences  between 
strata-specific  prevalence  estimates  were  evaluated  by 
assuming a Poisson distribution. We used SAS version 9.0 
(SAS Institute, Inc, Cary, North Carolina) for statistical 
analyses.  To  evaluate  latitude,  regression  analysis  was 
used to estimate the increase in MS prevalence for a unit 
increase (degree) in latitude.
Results
 
All practicing neurologists in the 3 study areas partici-
pated and provided medical records for review. Abstractors 
screened 1,434 medical records, and 670 records did not 
meet the screening criteria for date of office visit or place 
of residence. The remaining 764 records were abstracted 
and reviewed by the study neurologists to confirm MS. 
Of these, 608 (80%) were classified as definite or prob-
able MS. A small number of patients (7 in Texas, 17 in 
Missouri, and 4 in Ohio) had symptoms that suggested 
MS, but data were insufficient to satisfy the clinical cri-
teria.  These  cases  were  not  included  in  the  prevalence 
estimates.  In  Missouri,  approximately  20%  of  reviewed 
records were captured from tertiary care facilities with MS 
specialization facilities, compared with 54% in Texas and 
57% in Ohio.
 
Overall prevalence estimates for the study areas varied 
greatly; the prevalence was lowest in Texas (33°30′ north 
latitude), followed by Missouri (39°07′ north latitude), and 
highest in Ohio (41°24′ north latitude). Prevalence esti-
mates changed slightly after age-adjustment to the US or 
world standard populations, but the monotonic prevalence 
gradient remained consistent with the increase in US age-
adjusted prevalence per degree increase in latitude of 7.7 
(95% confidence interval [CI], −2.1 to 17.5) per 100,000 
population. For US age-adjusted estimates, the difference 
in prevalence per 100,000 population between Texas and 
Missouri was 39 (95% CI, 21-57), and the difference in 
prevalence per 100,000 between Missouri and Ohio was 
23 (95% CI, 3-54).
 
Race-adjusted  prevalence  estimates  for  the  3  areas 
showed a pattern similar to the age-adjusted estimates, 
although  the  difference  in  race-adjusted  prevalence 
between  Missouri  and  Ohio  was  only  16  (95%  CI,  −2.6 
to  35.1)  per  100,000  (Table).  Prevalence  was  higher  in 
non-Hispanic  whites  than  in  other  racial/ethnic  groups. 
In Texas, the difference in prevalence estimates between 
non-Hispanic whites and Hispanics was 45 (95% CI, 34-
56) per 100,000. In Ohio, the difference in prevalence esti-
mates between these 2 groups was 43 (95% CI, 8-79) per VOLUME 7: NO. 1
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100,000. The prevalence was lower in non-Hispanic blacks 
than in non-Hispanic whites in Texas, a difference of 34 
(95% CI, 14-54) per 100,000, but the prevalences in these 
groups were not significantly different in Ohio. Data from 
Missouri  concerning  prevalence  in  minority  populations 
were too sparse to draw any conclusions, possibly because 
of the smaller size of this study population. The MS preva-
lence was much higher in women than in men (4.1, 3.9, 
and 2.8 times as high in women in Texas, Missouri, and 
Ohio, respectively) (Table).
 
When evaluating the UV data, 46% of days were classi-
fied as high to extreme UV exposure in Texas (the south-
ernmost area with the lowest prevalence of MS), compared 
with 29% of days for Missouri (middle latitude) and 21% 
of days for Ohio (northern latitude) (P < .001, Cochran-
Armitage test for trend).
Discussion
 
In  the  United  States,  reported  prevalence  estimates 
for  MS  vary  widely,  which  may  reflect  differences  in 
ascertainment methods or in the underlying population 
structure (18,19). To the best of our knowledge, this is the 
first  study  to  simultaneously  estimate  population-based 
MS prevalence in 3 US communities by using the same 
ascertainment and case-verification methods. Our preva-
lence estimates reflect the range of estimates previously 
observed and support the reported geographic heterogene-
ity of MS prevalence in the United States and elsewhere 
(20,21).  The  northernmost  area  in  our  study  had  the 
highest MS prevalence, and the southernmost area had 
one of the lowest MS prevalences observed in recent US 
studies. Although the Lubbock area had a high proportion 
of Hispanics (a group in which the prevalence of MS may 
be low or underreporting may be high) (22), the prevalence 
for non-Hispanic whites was only 56.0 per 100,000.
 
Higher  prevalence  estimates  were  observed  among 
whites  than  among  blacks  in  the  Texas  area,  which  is 
similar  to  national  survey  data  in  the  United  States 
(6-8).  In  the  Ohio  area,  MS  prevalence  estimates  were 
similar for non-Hispanic whites and non-Hispanic blacks. 
Race/ethnicity was undetermined for 45 (14%) of the MS 
patients in Ohio. Even if all of these patients were non-
Hispanic whites, the resulting prevalence estimates per 
100,000 would be 117.9 for non-Hispanic whites, compared 
with 90.9 for non-Hispanic blacks. These revised estimates 
do not significantly differ, and the absolute difference in 
prevalence estimates by race for this area was still much 
lower than that observed in the Texas area or in previous 
US studies. The reason for this difference between study 
areas is unknown, and unfortunately, racial heterogene-
ity in the third study area was insufficient to explore this 
issue further. The difference in prevalence estimates for 
Hispanics in Texas and Ohio is also noteworthy, but the 
reason is unclear.
 
A previous report noted that if incidence studies were 
age-adjusted  to  a  common  population,  latitude  was  not 
associated  with  incidence  (18).  This  analysis  was  lim-
ited to 22 incidence studies, none from the United States. 
Prevalence  data  were  less  affected  by  age  adjustment; 
latitude  associations  remained  after  adjustment  to  the 
world population. These analyses included only prevalence 
studies from a single area in the United States at approxi-
mately 44° north latitude, and all studies were grouped 
by 10° latitude intervals. Furthermore, racial and ethnic 
differences  in  populations  studied  were  not  considered. 
Our  results,  even  after  age-adjustment,  demonstrate  a 
strong gradient within a small range in latitude, approxi-
mately 33° to 41° north latitude, with a prevalence ratio 
of 2.32 between the northern (Ohio) and southern (Texas) 
regions, similar to the relative risk of MS observed in US 
veterans according to where they lived when they joined 
the military (23). However, this study and others suggest 
that the latitude gradient in the United States and other 
parts of the world is not as steep as previously suspected. 
These studies also suggest an increasing risk of MS in 
nonwhites, which emphasizes that prevalence estimates 
must be adjusted for sex and race (20,24).
 
The  geographic  distribution  of  MS  is  interpreted  by 
some researchers as reflecting differences in the distribu-
tion of genetically susceptible populations, as determined 
by racial and ethnic backgrounds (25,26). Our study areas 
showed a geographic gradient even when we restricted the 
analysis to non-Hispanic whites, but we could not charac-
terize patient ancestry. Migration studies suggest an asso-
ciation between geography and MS risk (27,28), but unless 
migration patterns were differential between regions, this 
association would not explain our findings.
 
Differences in environmental risk could also influence 
geographic variation in MS prevalence, and some stud-
ies  have  postulated  that  UV  exposure  could  influence 
this variation. The geographic gradient in MS prevalence VOLUME 7: NO. 1
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in Australia correlates strongly with UV exposure  (16). 
Similarly, in a US case-control study, high levels of resi-
dential and occupational sunlight exposure were inversely 
associated  with  risk  of  MS  (15).  Our  data  support  this 
inverse association between UV exposure and MS preva-
lence, although the mechanism by which UV exposure may 
influence MS risk is unknown (16). UV exposure is only 1 
of several factors that could explain the epidemiologic fea-
tures of MS, but such questions cannot be answered with 
this ecologic analysis.
 
This project had several strengths. First, the application 
of consistent case-finding and case-verification method to 
3 geographically distinct areas allowed us to evaluate the 
previously reported latitude gradient for MS. We captured 
age- and sex-specific prevalence estimates, which allows 
adjusted comparisons with MS prevalence studies world-
wide. Second, we captured race/ethnicity data for 89% of 
cases,  allowing  for  an  evaluation  of  racial/ethnic  differ-
ences in MS prevalence. Finally, medical records review 
usually  provided  sufficient  data  to  verify  MS  diagnosis 
according  to  rigid  clinical  criteria.  This  cost-  and  time-
effective approach to data gathering had high specificity 
for identifying MS cases.
 
Although our use of a rigid case definition enhanced spec-
ificity, it may have reduced sensitivity of ascertainment. 
Although abstracted records typically included extensive 
case histories, some borderline cases would have required a 
clinical visit for accurate diagnosis, and some records may 
have  contained  insufficient  information  if  patients  had 
recently  changed  physicians.  For  the  3  areas  combined, 
however, less than 4% of reviewed records strongly sug-
gested MS but data were insufficient to classify them as 
definite or probable. If the final case counts included all 
these records, the crude prevalence estimates per 100,000 
would be 44 in Texas, 102 in Missouri, and 114 in Ohio.
 
Because the primary data source was neurologists’ prac-
tices and neurology departments of tertiary care facilities, 
some cases were probably missed (29), particularly among 
the small proportion of patients with benign disease or 
relapsing-remitting  MS  in  sustained  remission.  These 
patients may not regularly seek neurologic care and may 
not have been captured during our study period, and a 
longer study period may have captured less severe MS 
cases.  Few  cases  were  captured  through  general  physi-
cians because we did not actively pursue this source. We 
may have also missed MS patients who did not have access 
to the health care system. The sites differed with respect 
to  the  proportion  of  private  neurology  practices  versus 
tertiary-care facilities as the source of case ascertainment, 
which could lead to differences in the completeness of case 
ascertainment.  Regardless  of  differences  in  the  medical 
communities serving the respective areas, however, both 
of these sources are considered the most appropriate data 
sources (29). Where estimates of MS prevalence exist for 
regions of similar latitude, our prevalence estimates are 
similar (29,30).
 
Our study established the feasibility of using a uniform 
method  for  case  ascertainment  in  different  geographic 
regions and demonstrated that the distribution of MS var-
ies with respect to geography, sex, and race/ethnicity. It pro-
vides necessary background prevalence estimates for clus-
ter investigations while establishing baseline estimates for 
future studies evaluating temporal trends in prevalence.
Acknowledgments
 
This  study  was  funded  by  the  Agency  for  Toxic 
Substances and Disease Registry (U50/ATU799115, U50/
ATU689131, and U50/ATU589105).
Author Information
 
Corresponding  Author:  Dhelia  M.  Williamson,  PhD, 
Centers for Disease Control and Prevention, 1600 Clifton 
Rd, Mailstop K-23, Atlanta, GA 30333. Telephone: 770-
488-2440. E-mail: DWilliamson1@cdc.gov.
 
Author Affiliations: Curtis W. Noonan, Agency for Toxic 
Substances and Disease Registry, Atlanta, Georgia; Judy 
P. Henry, Laurie Wagner, Texas Department of Health, 
Austin, Texas; Robert Indian, Ohio Department of Health, 
Columbus,  Ohio;  Sharon  G.  Lynch,  John  S.  Neuberger, 
University  of  Kansas  School  of  Medicine,  Kansas  City, 
Kansas; Randolph Schiffer, Texas Tech University Health 
Sciences Center, Lubbock, Texas; Janine Trottier, Lorain 
County General Health District, Elyria, Ohio; Ruth Ann 
Marrie, Cleveland Clinic, Cleveland, Ohio.
References
 1.  Dean G. How many people in the world have multiple VOLUME 7: NO. 1
JANUARY 2010
  Centers for Disease Control and Prevention • www.cdc.gov/pcd/issues/2010/jan/08_0241.htm
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the US Department of Health and Human Services, the 
Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only and 
does not imply endorsement by any of the groups named above.
sclerosis? Neuroepidemiology 1994;13(1-2):1-7.
 2.  Weinshenker BG. Epidemiology of multiple sclerosis. 
Neurol Clin 1996;14(2):291-308.
 3.  Lublin FD, Reingold SC. Defining the clinical course of 
multiple sclerosis: results of an international survey. 
National  Multiple  Sclerosis  Society  (USA)  Advisory 
Committee on Clinical Trials of New Agents in Multiple 
Sclerosis. Neurology 1996;46(4):907-11.
 4.  Weinshenker  BG,  Bass  B,  Rice  GP,  Noseworthy  J, 
Carriere W, Baskerville J, et al. The natural history 
of  multiple  sclerosis:  a  geographically  based  study. 
I.  Clinical  course  and  disability.  Brain  1989;112(Pt 
1):133-46.
 5.  Thompson AJ, Polman CH, Miller DH, McDonald WI, 
Brochet B, Filippi M, et al. Primary progressive mul-
tiple sclerosis. Brain 1997;120(Pt 6):1085-96.
 6.  Baum HM, Rothschild BB. The incidence and prev-
alence  of  reported  multiple  sclerosis.  Ann  Neurol 
1981;10(5):420-8.
 7.  Anderson DW, Ellenberg JH, Leventhal CM, Reingold 
SC,  Rodriguez  M,  Silberberg  DH.  Revised  estimate 
of the prevalence of multiple sclerosis in the United 
States. Ann Neurol 1992;31(3):333-6.
 8.  Noonan  CW,  Kathman  SJ,  White  MC.  Prevalence 
estimates for MS in the United States and evidence of 
an increasing trend for women. Neurology 2002;58(1): 
136-8.
 9.  Williamson  DM,  Henry  JP.  Challenges  in  address-
ing  community  concerns  regarding  clusters  of  mul-
tiple sclerosis and potential environmental exposures. 
Neuroepidemiology 2004;23(5):211-6.
10. Mayr  WT,  Pittock  SJ,  McClelland  RL,  Jorgensen 
NW,  Noseworthy  JH,  Rodriguez  M.  Incidence  and 
prevalence of multiple sclerosis in Olmsted County, 
Minnesota, 1985-2000. Neurology 2003;61(10):1373-7.
11. Multiple sclerosis among Lorain County, Ohio, resi-
dents  1998-2000.  Atlanta  (GA):  Agency  for  Toxic 
Substances and Disease Registry; 2005.
12. Multiple  sclerosis  prevalence:  Independence  and 
Sugar Creek, Missouri. Atlanta (GA): Agency for Toxic 
Substances and Disease Registry; 2004.
13. Multiple sclerosis pilot surveillance: 19 Texas coun-
ties. Atlanta (GA): Agency for Toxic Substances and 
Disease Registry; 2004.
14. Poser  CM,  Paty  DW,  Scheinberg  L,  McDonald  WI, 
Davis FA, Ebers GC, et al. New diagnostic criteria for 
multiple  sclerosis:  guidelines  for  research  protocols. 
Ann Neurol 1983;13(3):227-31.
15. Freedman DM, Dosemeci M, Alavanja MC. Mortality 
from  multiple  sclerosis  and  exposure  to  residen-
tial  and  occupational  solar  radiation:  a  case-control 
study based on death certificates. Occup Environ Med 
2000;57(6):418-21.
16. van der Mei IA, Ponsonby AL, Blizzard L, Dwyer T. 
Regional variation in multiple sclerosis prevalence in 
Australia and its association with ambient ultraviolet 
radiation. Neuroepidemiology 2001;20(3):168-74.
17. National  Weather  Service.  UV  index:  annual  time 
series. 2004.
18. Zivadinov  R,  Iona  L,  Monti-Bragadin  L,  Bosco  A, 
Jurjevic  A,  Taus  C,  et  al.  The  use  of  standardized 
incidence  and  prevalence  rates  in  epidemiological 
studies on multiple sclerosis. A meta-analysis study. 
Neuroepidemiology 2003;22(1):65-74.
19. Klein RJ, Schoenborn CA. Age adjustment using the 
2000 projected US population. Healthy People 2010 
Stat Notes 2001(20):1-10.
20. Hernan MA, Olek MJ, Ascherio A. Geographic varia-
tion of MS incidence in 2 prospective studies of US 
women. Neurology 1999;53(8):1711-8.
21. Rosati G. The prevalence of multiple sclerosis in the 
world: an update. Neurol Sci 2001;22(2):117-39.
22. Enstrom  JE,  Operskalski  EA.  Multiple  sclerosis 
among  Spanish-surnamed  Californians.  Neurology 
1978;28(5):434-8.
23. Wallin  MT,  Page  WF,  Kurtzke  JF.  Multiple  scle-
rosis  in  US  veterans  of  the  Vietnam  era  and  later 
military service: race, sex, and geography. Ann Neurol 
2004;55(1):65-71.
24. Alonso A, Hernan MA. Temporal trends in the inci-
dence  of  multiple  sclerosis:  a  systematic  review. 
Neurology 2008;71(2):129-35.
25. McGuigan C, Dunne C, Crowley J, Hagan R, Rooney 
G, Lawlor E, et al. Population frequency of HLA haplo-
types contributes to the prevalence difference of multi-
ple sclerosis in Ireland. J Neurol 2005;252(10):1245-8.
26. Ebers GC, Sadovnick AD. The geographic distribution 
of  multiple  sclerosis:  a  review.  Neuroepidemiology 
1993;12(1):1-5.
27. Ascherio A, Munger KL. Environmental risk factors 
for  multiple  sclerosis.  Part  II:  noninfectious  factors. 
Ann Neurol 2007;61(6):504-13.
28. Ascherio A, Munger KL. Environmental risk factors 
for multiple sclerosis. Part I: the role of infection. Ann 
Neurol 2007;61(4):288-99.
29. Nelson LM, Hamman RF, Thompson DS, Baum HM, 
Boteler  DL,  Burks  JS,  et  al.  Higher  than  expected 
prevalence of multiple sclerosis in northern Colorado: VOLUME 7: NO. 1
JANUARY 2010
  www.cdc.gov/pcd/issues/2010/jan/08_0241.htm • Centers for Disease Control and Prevention  7
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the US Department of Health and Human Services, the 
Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only and 
does not imply endorsement by any of the groups named above.
dependence on methodologic issues. Neuroepidemiology 
1986;5(1):17-28.
30. Turabelidze  G,  Schootman  M,  Zhu  BP,  Malone  JL, 
Horowitz  S,  Weidinger  J,  et  al.  Multiple  sclerosis 
prevalence and possible lead exposure. J Neurol Sci 
2008;269(1-2):158-62.
Table
Table. Cases of Multiple Sclerosis and Respective Strata-Specific and Adjusted Prevalence Estimates for 3 Areas, 1998-2000
Characteristic
Texas (Lubbock and 19-County 
Surrounding Area) Missouri (Independence and Sugar Creek) Ohio (Lorain County)
No. of 
Casesa Population
Prevalence per 
100,000  
(95% CI)
No. of 
Casesa Population
Prevalence per 
100,000 (95% CI)
No. of 
Casesa Population
Prevalence per 
100,000 (95% CI)
Sex
Women 147 214,2 8. (8.0-80.) 8 2,870 1.8 (109.-
19.2)
27 14,017 1.4 (142.2-
184.)
Men  210,81 1. (11.-2.1) 20 7,929 4. (21.-.2) 8 19,47 9.4 (4.4-72.4)
Age, y
<0 19 201,420 9.4 (.7-14.7) 4 47,8 8.4 (2.4-21.7) 10 11,24 8. (4.0-1.9)
0-9  7,282 7. (9.7-80.9) 1 17,244 7.4 (40.-129.1) 4 42,48 80.0 (2.4-107.)
40-49 9 7,29 10.1 (78.-
12.9)
40 18,172 220.1 (1.9-
299.7)
97 4, 212.4 (19.-
2.)
0-9 49 40,89 119.9 (88.7-
18.)
4 14,078 241. (17.-
7.0)
102 ,274 0. (24.8-
7.2)
0-9 17 0,7 .4 (2.-88.7) 11 10,247 107. (.-192.) 40 21,088 189.7 (129.7-
249.7)
≥70 4 7,40 10.7 (2.9-27.4) 4 1,7 29.9 (7.9-7.8) 7 2,900 142.9 (9.9-189.9)
Unknown 1 NC NC 0 NC NC 0 NC NC
Race/ethnicity
Hispanic 1 142,448 11.2 (.4-18.2) 0 2,40 NC 11 19,42 .0 (21.-90.7)
Non-Hispanic 
white
140 249,882 .0 (47.1-.1) 104 108,97 9. (77.9-11.) 242 24,88 99.4 (8.-112.2)
Non-Hispanic 
black
 27,17 22.1 (8.1-48.1) 1 2,984 NC 22 24,19 90.9 (2.1-129.7)
Other/
unknown
20 NC NC 1 ,408 NC 4 NC NC
 
Abbreviations: CI, confidence interval; NC, not calculable. 
a Cases include diagnoses of definite or probable MS according to the Poser 198 criteria (14). 
b Directly race-adjusted to the 2000 US population. Cases with missing/unknown data on race/ethnicity (20 in Texas, 1 in Missouri, and 4 in Ohio) were not 
included in specific strata for race/ethnicity prevalence. 
c Directly age-adjusted to the 2000 US population. 
d Directly age-adjusted to the 2000 world population. To calculate age-adjusted prevalence, cases with missing data on age (1 in Texas and  in Ohio) were 
assumed to be in the age group with highest prevalence, 0-9 years.
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Characteristic
Texas (Lubbock and 19-County 
Surrounding Area) Missouri (Independence and Sugar Creek) Ohio (Lorain County)
No. of 
Casesa Population
Prevalence per 
100,000  
(95% CI)
No. of 
Casesa Population
Prevalence per 
100,000 (95% CI)
No. of 
Casesa Population
Prevalence per 
100,000 (95% CI)
Crude overall 182 424,91 42.8 (.8-49.) 10 120,799 87.7 (71.-10.4) 20 284,4 112.4 (99.8-12.0)
Race- 
adjustedb
12 NC 44.2 (7.2-1.2) 10 NC 72. (7.2-88.0) 27 NC 88.9 (78.1-99.7)
US age- 
adjustedc
182 NC 47.2 (40.-4.1) 10 NC 8. (9.8-102.8) 20 NC 109. (97.-121.)
World age-
adjustedd
182 NC 9.9 (4.0-4.7) 10 NC 70. (.9-84.) 20 NC 8. (7.8-9.2)
 
Abbreviations: CI, confidence interval; NC, not calculable. 
a Cases include diagnoses of definite or probable MS according to the Poser 198 criteria (14). 
b Directly race-adjusted to the 2000 US population. Cases with missing/unknown data on race/ethnicity (20 in Texas, 1 in Missouri, and 4 in Ohio) were not 
included in specific strata for race/ethnicity prevalence. 
c Directly age-adjusted to the 2000 US population. 
d Directly age-adjusted to the 2000 world population. To calculate age-adjusted prevalence, cases with missing data on age (1 in Texas and  in Ohio) were 
assumed to be in the age group with highest prevalence, 0-9 years.
Table. (continued) Cases of Multiple Sclerosis and Respective Strata-Specific and Adjusted Prevalence Estimates for 3 Areas, 
1998-2000